Columbia-based Xcision Medical Systems develops stereotactic radiotherapy technology focused specifically on breast cancer, led by its GammaPod system for early-stage disease. Developed from a patent licensed from the University of Maryland School of Medicine, GammaPod uses focused, noninvasive radiation and is designed to shorten treatment to as few as five days. The system has received FDA 510(k) clearance and carries the CE Mark in Europe.
FDA 510(k) clearance
compliance_program
CE Mark
certification